BAJAJ BROKING
Biocon obtains FDA approval for Micafungin injectable drug, strengthening its antifungal medication portfolio. Micafungin is an antifungal medication utilised to treat various fungal and yeast infections. In FY24, Biocon’s consolidated net profit rose to ₹1,022 crore from ₹463 crore in FY23.
Biotechnology firm Biocon Ltd announced on Monday that it has secured approval from the US Food and Drug Administration (US FDA) for its vertically integrated, complex injectable product micafungin, available in 50mg and 100mg vials. The approval enhances Biocon's portfolio of antifungal medications.
Explore: BIOCON LIMITED
Micafungin is an antifungal medication utilised to treat various fungal and yeast infections. This approval underscores Biocon's commitment to providing effective solutions for combating fungal and yeast-related ailments.
Biocon reported a 57% decline in its consolidated net profit to ₹136 crore for the fourth quarter ended March 2024. This decrease was primarily attributed to higher expenses. Total revenue for the quarter saw a marginal increase to ₹3,966 crore compared to ₹3,929 crore in the previous year.
For the fiscal year ended on March 31, 2024, Biocon witnessed a significant improvement in its consolidated net profit, which rose to ₹1,022 crore from ₹463 crore in the previous fiscal year. Total revenue also saw a substantial increase, reaching ₹15,621 crore compared to ₹11,550 crore in the 2022-23 fiscal year.
While the FDA approval for the Micafungin injectable drug highlights Biocon's progress in expanding its product offerings, the decline in net profit reflects the challenges posed by higher expenses. Nonetheless, the company's overall yearly performance demonstrates growth and resilience in the face of economic fluctuations.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Share Market Today | Gift Nifty Signals 100-Point Gap Down, Nifty to Consolidate
06 Sep, 2024 | 4 Min. read
KEC International Secures ₹1,423 Cr Transmission Line Order in Saudi Arabia
06 Sep, 2024 | 1 Min. read
Ashoka Buildcon’s Viva Highways Monetises Pune Land for ₹453 Crore
06 Sep, 2024 | 2 Min. read
Peak Partners To Sell 11% Stake in Indigo Paints via Block Deal
06 Sep, 2024 | 2 Min. read
US Initial Jobless Claims Drop to 227,000 in August.
06 Sep, 2024 | 1 Min. read
Commodities Market Today | WTI Crude Steady at $69.18, Gold Rises 0.8% to $2,546
06 Sep, 2024 | 1 Min. read
Gold Rate Today | Gold Rises 0.8% to $2,546, Silver Gains 2% to $29.14
06 Sep, 2024 | 2 Min. read
Vodafone Idea Share Price Falls 11% After Goldman Sachs Report
06 Sep, 2024 | 1 Min. read
Suzlon Energy Share Price Rises After Corporate Office Sale
06 Sep, 2024 | 1 Min. read
Why is the Stock Market Down Today? Key Factors Explained
06 Sep, 2024 | 1 Min. read
Sona BLW Precision Forgings Plans ₹2,400 Crore QIP at ₹675-700 per Share
05 Sep, 2024 | 1 Min. read
Commodities Market Today | Crude Oil Drops, Brent Hits Low; Gold and Silver Rise
05 Sep, 2024 | 1 Min. read
Analysis to Become a Pro Investor
28 Dec, 2023 | 4 Min. read
Women In Real Estate Investing (Investree)
28 Dec, 2023 | 5 Min. read
How To Check Prudent Corporate Advisory IPO Allotment Status
27 Dec, 2023 | 3 Min. read
How To Boost Credit Score? – Steps to Improve Creditworthiness
27 Dec, 2023 | 4 Min. read
Advantages and Disadvantages of Opening Multiple Demat Accounts
26 Dec, 2023 | 4 Min. read
7th CPC LTC: Leave Travel Concession Rules for Central Government Employees
26 Dec, 2023 | 4 Min. read
7th Pay Commission: House Building Advance (HBA) Interest Rate FY 2023-24
26 Dec, 2023 | 5 Min. read
The Future of Trading: Exploring Bajaj Broking’s Demat Features
26 Dec, 2023 | 6 Min. read
7th Central Pay Commission Cpc Fitment Table
23 Dec, 2023 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading